Symbol="PRLD"
AssetType="Common Stock"
Name="Prelude TherapeuticsÂ Inc"
Description="Prelude Therapeutics Incorporated, a precision clinical-stage oncology company, focuses on the discovery and development of small molecule therapies optimized to target key drivers in cancers. The company is headquartered in Wilmington, Delaware."
CIK="1678660"
Exchange="NASDAQ"
Currency="USD"
Country="USA"
Sector="LIFE SCIENCES"
Industry="PHARMACEUTICAL PREPARATIONS"
Address="200 POWDER MILL ROAD, WILMINGTON, DE, US"
FiscalYearEnd="December"
LatestQuarter="2023-03-31"
MarketCapitalization="234459000"
EBITDA="-121072000"
PERatio="None"
PEGRatio="None"
BookValue="3.668"
DividendPerShare="0"
DividendYield="0"
EPS="-2.17"
RevenuePerShareTTM="0"
ProfitMargin="0"
OperatingMarginTTM="0"
ReturnOnAssetsTTM="-0.319"
ReturnOnEquityTTM="-0.52"
RevenueTTM="0"
GrossProfitTTM="0"
DilutedEPSTTM="-2.17"
QuarterlyEarningsGrowthYOY="0"
QuarterlyRevenueGrowthYOY="0"
AnalystTargetPrice="10.75"
TrailingPE="-"
ForwardPE="-"
PriceToSalesRatioTTM="-"
PriceToBookRatio="1.145"
EVToRevenue="-"
EVToEBITDA="-0.214"
Beta="0.352"
num_52WeekHigh="8.9"
num_52WeekLow="4.245"
num_50DayMovingAverage="5.52"
num_200DayMovingAverage="6.13"
SharesOutstanding="39601500"
DividendDate="None"
ExDividendDate="None"
symbol="PRLD"
open="4.60"
high="4.67"
low="4.49"
price="4.64"
volume="39143.00"
latest_trading_day="2023-07-13"
previous_close="4.61"
change="0.03"
change_percent="0.6508%"
aroon_positive_momentum_days="0"
aroon_negative_momentum_days="38"
trend_strength="Absent or Weak Trend"
buying_signal="Strong Sell Signal"
volume_analysis="Target Volume"
value_analysis="Expected Range"
Aroon_change="FALSE"
Aroon_momentum="62"
Volume_recent_avg="105175"
Change_recent_avg="0.01"
Delta_recent_avg="0.5"
Variance_recent_avg="0.25"
Change_ratio_recent_avg="-0.18"
RSI_change="FALSE"
ADX_change="FALSE"

event="FALSE"
Aroon_signal="negative"
Aroon_change="FALSE"
Aroon_momentum_positive="62"
Aroon_momentum_negative="38"
image_negative_thumbnail_id_1="1159"
image_negative_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Negative_Landscape_0193.jpeg"
image_negative_thumbnail_id_2="143"
image_negative_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/05/MI_Finance_Negative_Landscape_0033.jpeg"
image_neutral_thumbnail_id_1="537"
image_neutral_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Neutral_Landscape_0062.jpeg"
image_neutral_thumbnail_id_2="574"
image_neutral_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Neutral_Landscape_0025.jpeg"
image_positive_thumbnail_id_1="647"
image_positive_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Positive_Landscape_0061.jpeg"
image_positive_thumbnail_id_2="987"
image_positive_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Positive_Landscape_0149.jpeg"
image_professor_thumbnail_id_1="1191"
image_professor_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Professor_Landscape_0025.jpeg"
image_professor_thumbnail_id_2="1192"
image_professor_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Professor_Landscape_0026.jpeg"
